Irreversible Electroporation of Hepatic Malignancy

Overview

Journal Semin Intervent Radiol

Specialty Radiology

Date 2014 Jan 18

PMID 24436519

Citations 18

Authors

Govindarajan Narayanan

Tatiana Froud

Rekhaben Suthar

Katuska Barbery

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a worldwide problem of epidemic proportions, best treated in a multidisciplinary setting. Major advances have been made in all specialties that manage patients with HCC, with surgical options at one end of the spectrum and palliative chemotherapy on the other, and the vast majority of patients require the involvement and expertise of interventional oncology. Several ablative and transarterial technologies are currently available. Irreversible electroporation (IRE) is a new ablative technology that uses high-voltage, low-energy DC current to create nanopores in the cell membrane, disrupting the homeostasis mechanism and inducing cell death by initiating apoptosis. This article discusses the evolution of IRE as well as its safety and efficacy in the context of other ablative therapies in the treatment of hepatic malignancies.

Citing Articles

Investigation of the Bystander Effect on Cell Viability After Application of Combined Electroporation-Based Methods.

Barauskaite-Sarkiniene N, Novickij V, Satkauskas S, Ruzgys P Int J Mol Sci. 2025; 26(5).

PMID: 40076917 PMC: 11900407. DOI: 10.3390/ijms26052297.

Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study Protocol.

Kalra N, Bhujade H, Baloji A, Khosla D, Samra S, Srinivasan R Cardiovasc Intervent Radiol. 2024; 47(11):1532-1539.

PMID: 39333372 DOI: 10.1007/s00270-024-03856-0.

Nanoplatforms Potentiated Ablation-Immune Synergistic Therapy through Improving Local Control and Suppressing Recurrent Metastasis.

Wei Z, Yu X, Huang M, Wen L, Lu C Pharmaceutics. 2023; 15(5).

PMID: 37242696 PMC: 10224284. DOI: 10.3390/pharmaceutics15051456.

Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy.

Liu Y, Chou B, Yalamanchili A, Lim S, Dawson L, Thomas T J Clin Med. 2023; 12(10).

PMID: 37240623 PMC: 10218854. DOI: 10.3390/jcm12103517.

Pulse Parameters and Thresholds for (ir)Reversible Electroporation on Hepatocellular Carcinoma Cells .

Lindelauf K, Baragona M, Baumann M, Maessen R, Ritter A Technol Cancer Res Treat. 2023; 22:15330338221136694.

PMID: 36600679 PMC: 9829997. DOI: 10.1177/15330338221136694.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Cho Y, Kim J, Kim M, Rhim H, Han J . Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2008; 49(2):453-9. DOI: 10.1002/hep.22648. View

Narayanan G, Hosein P, Arora G, Barbery K, Froud T, Livingstone A . Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012; 23(12):1613-21. DOI: 10.1016/j.jvir.2012.09.012. View

Yao F, Bass N, Nikolai B, Davern T, Kerlan R, Wu V . Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002; 8(10):873-83. DOI: 10.1053/jlts.2002.34923. View

Seeff L . Introduction: The burden of hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S1-4. DOI: 10.1053/j.gastro.2004.09.010. View

Kingham T, Karkar A, DAngelica M, Allen P, DeMatteo R, Getrajdman G . Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012; 215(3):379-87. DOI: 10.1016/j.jamcollsurg.2012.04.029. View

Narayanan G, Froud T, Lo K, Barbery K, Perez-Rojas E, Yrizarry J . Pain analysis in patients with hepatocellular carcinoma: irreversible electroporation versus radiofrequency ablation-initial observations. Cardiovasc Intervent Radiol. 2012; 36(1):176-82. DOI: 10.1007/s00270-012-0426-9. View

Davila J, Morgan R, Shaib Y, McGlynn K, El-Serag H . Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 2005; 54(4):533-9. PMC: 1774454. DOI: 10.1136/gut.2004.052167. View

Rubinsky B, Onik G, Mikus P . Irreversible electroporation: a new ablation modality--clinical implications. Technol Cancer Res Treat. 2007; 6(1):37-48. DOI: 10.1177/153303460700600106. View

10.

Goldberg S, Dupuy D . Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. J Vasc Interv Radiol. 2001; 12(9):1021-32. DOI: 10.1016/s1051-0443(07)61587-5. View

11.

Lee E, Chen C, Prieto V, Dry S, Loh C, Kee S . Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation. Radiology. 2010; 255(2):426-33. DOI: 10.1148/radiol.10090337. View

12.

Bosch F, Ribes J, Diaz M, Cleries R . Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127(5 Suppl 1):S5-S16. DOI: 10.1053/j.gastro.2004.09.011. View

13.

Mir L, Orlowski S, BELEHRADEK Jr J, Paoletti C . Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer. 1991; 27(1):68-72. DOI: 10.1016/0277-5379(91)90064-k. View

14.

Davalos R, Mir I, Rubinsky B . Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005; 33(2):223-31. DOI: 10.1007/s10439-005-8981-8. View

15.

Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A . Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg. 2000; 190(5):580-7. DOI: 10.1016/s1072-7515(00)00251-9. View

16.

Rimola J, Forner A, Tremosini S, Reig M, Vilana R, Bianchi L . Non-invasive diagnosis of hepatocellular carcinoma ≤ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. J Hepatol. 2012; 56(6):1317-23. DOI: 10.1016/j.jhep.2012.01.004. View

17.

Llovet J, Bruix J . Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48 Suppl 1:S20-37. DOI: 10.1016/j.jhep.2008.01.022. View

18.

Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R . Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006; 43(5):1101-8. DOI: 10.1002/hep.21164. View

19.

Thomson K, Cheung W, Ellis S, Federman D, Kavnoudias H, Loader-Oliver D . Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011; 22(5):611-21. DOI: 10.1016/j.jvir.2010.12.014. View

20.

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View